ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADMA is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical setup is weak, sentiment is pressured by multiple securities-fraud investigations, and Wall Street has trimmed price targets even while keeping bullish ratings. Since the user is impatient and wants a direct call, my view is to hold off rather than buy now.
The stock closed at 8.0636, below the pivot resistance at 8.323 and under both short- and long-term trend pressure. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), which confirms the broader trend is still weak. MACD histogram is slightly positive and expanding, suggesting some short-term stabilization, but RSI_6 at 23.733 indicates the stock is oversold rather than showing a strong reversal. Key levels: support at 7.973 and 7.758, resistance at 8.673 and 8.888. Overall, the trend is not strong enough to justify an aggressive long-term entry today.
Hedge funds are buying aggressively, with buying up 719.51% over the last quarter. Analyst firms such as Mizuho and Canaccord still maintain positive ratings and see upside from current levels. Canaccord also noted that Asceniv held up relatively well in 1Q26, which supports the longer-term product story. The stock is also oversold technically, which can support a bounce.
The biggest negative catalyst is the cluster of recent securities-fraud investigations from Bleichmar Fonti & Auld, Pomerantz, and Rosen, all tied to allegations around reported revenue growth and channel stuffing. Cantor Fitzgerald recently downgraded the stock to Neutral after the short-report controversy and concerns about receivables and disclosure quality. Zacks also added ADMA to its Strong Sell list due to downward earnings estimate revisions. Similar-stock trend data also points to near-term weakness, with a negative expected performance over the next day, week, and month.
No usable financial snapshot was provided because of an error, so the latest quarter financials cannot be fully assessed. From the analyst commentary, however, 1Q26 was described as a reset quarter with results falling short and guidance lowered, mainly due to pressure on Bivigam in the standard IG market. The key product Asceniv reportedly held up fairly well, which suggests the core growth driver is still intact, but near-term growth quality appears under pressure. Latest quarter season: 1Q26.
Analyst sentiment is still mixed-to-positive, but targets have been cut recently. Mizuho lowered its target to $20 from $24 and kept Outperform. Canaccord lowered its target to $18 from $21 but kept Buy, and had earlier initiated Buy with a $21 target. Earlier, Mizuho also cut from $30 to $24, and Cantor downgraded to Neutral amid fraud allegations. Wall Street pros and cons view: the bull case is still centered on Asceniv growth, margin improvement, and favorable risk/reward; the bear case is focused on revenue-recognition concerns, possible channel stuffing, weaker guidance, and damaged credibility.
